Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation
Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...
894 Views
MabPharm (迈博医药) IPO: Fairly Valued and Lacks Biotech Investors
MabPharm, a biotech company backed by CDH Investment, launched book building today. In our previous insights, we have discussed the company's...
704 Views
Hansoh Pharma (翰森制药) IPO: New Numbers, Pre-IPO Dividend and Boyu Investment (Part 3)
Hansoh Pharma re-filed prospectus in April and is targeting a listing by summer. In our previous insight, we covered the company's major products...
978 Views
MabPharma (迈博医药) IPO: Assembled for a Trade?
MabPharma, backed by Chinese private equity investor CDH, is seeking to list in Hong Kong. In this insight, we will discuss the following...
972 Views
HLX02: Innovation Could Overtake
The oncology treatment landscape in China is evolving rapidly as the government has prioritized access to innovative drugs to meet this significant...
704 Views